BENDEKA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) — efficacy relative to first-line therapies other than chlorambucil has not been established — or patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen.
The information on this site is intended for healthcare professsionals
in the United States. Are you a healthcare professional in the United States?
For healthcare professionals or patients with specific medical questions about BENDEKA® (bendamustine HCl) injection, please contact:
1-888-4-TEVARX (1-888-483-8279)
To request more information about BENDEKA, click here.
You are about to leave BENDEKA.com and enter a website operated by a third party.
Would you like to continue?
